Jakub Tolar

Skin-Targeted Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa

National Institute of Arthritis and Musculoskeletal and Skin Diseases · R01

Contact PI · $4.5M · University of Minnesota

Off-the-Shelf Immune Effector Cells for Hematological Malignancies

National Cancer Institute · P01

Project lead · $2.9M · University of Minnesota

Genetic Mapping of Cellular Trait Variation in Single Human Individuals

National Human Genome Research Institute · R21

PI · $423.5K · University of Minnesota

Stem Cell Biology Training Program

National Institute of General Medical Sciences · T32

PI · $52.4K · University of Minnesota

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Principal investigator · Completed · Phase 1, Phase 2

RHEACELL GmbH & Co. KG

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Principal investigator · Completed · Phase 2

Masonic Cancer Center, University of Minnesota

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Principal investigator · Completed · Phase 1, Phase 2

Masonic Cancer Center, University of Minnesota

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Principal investigator · Terminated · Phase 2

Masonic Cancer Center, University of Minnesota